Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P07196
UPID:
NFL_HUMAN
Alternative names:
68 kDa neurofilament protein; Neurofilament triplet L protein
Alternative UPACC:
P07196; B9ZVN2; Q16154; Q8IU72
Background:
Neurofilament light polypeptide, also known as 68 kDa neurofilament protein, plays a crucial role in the maintenance of neuronal caliber alongside NEFM and NEFH. It potentially cooperates with PRPH and INA to form neuronal networks, essential for nerve function.
Therapeutic significance:
Linked to Charcot-Marie-Tooth disease types 1F, 2E, and dominant intermediate G, this protein's variants influence disease manifestation. Understanding its role could lead to targeted therapies for these peripheral nervous system disorders.